» Articles » PMID: 37622592

Progress in Atrial Fibrillation Ablation During 25 Years of Europace Journal

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

The first edition of Europace journal in 1999 came right around the time of the landmark publication of the electrophysiologists from Bordeaux, establishing how elimination of ectopic activity from the pulmonary veins (PVs) resulted in a marked reduction of atrial fibrillation (AF). The past 25 years have seen an incredible surge in scientific interest to develop new catheters and energy sources to optimize durability and safety of ablation, as well as study the mechanisms for AF and devise ablation strategies. While ablation in the beginning was performed with classic 4 mm tip catheters that emitted radiofrequency (RF) energy to create tissue lesions, this evolved to using irrigation and contact force (CF) measurement while increasing power. Also, so-called single-shot devices were developed with balloons and arrays to create larger contiguous lesions, and energy sources changed from RF current to cryogenic ablation and more recently pulsed field ablation with electrical current. Although PV ablation has remained the basis for every AF ablation, it was soon recognized that this was not enough to cure all patients, especially those with non-paroxysmal AF. Standardized approaches for additional ablation targets have been used but have not been satisfactory in all patients so far. This led to highly technical mapping systems that are meant to unravel the drivers for the maintenance of AF. In the following sections, the development of energies, strategies, and tools is described with a focus on the contribution of Europace to publish the outcomes of studies that were done during the past 25 years.

Citing Articles

Thermal side effects during pulsed field ablation: an analysis using computer modelling.

Mercado-Montoya M, Gomez-Bustamante T, Mickelsen S, Kulstad E, Gonzalez-Suarez A, Overzet L Europace. 2025; 27(3).

PMID: 39960855 PMC: 11879925. DOI: 10.1093/europace/euaf035.


Comparative analysis of anaesthesia modalities in pulmonary vein isolation: insights from a prospective multicentre registry.

Massalha E, Dakka A, Sabbag A, Berkovitch A, Marai I, Michowitz Y Europace. 2025; 27(2).

PMID: 39957475 PMC: 11831030. DOI: 10.1093/europace/euae301.


Impact of atrial fibrillation diagnosis-to-ablation time on 24-month efficacy and safety outcomes in the Cryo Global Registry.

Lawin D, Stellbrink C, Chun K, Chun K, Li C, van Bragt K Europace. 2025; 27(2).

PMID: 39836630 PMC: 11795645. DOI: 10.1093/europace/euaf008.


Freeze the clock: earlier catheter ablation for atrial fibrillation delivers better outcomes.

Schiavone M, Di Biase L Europace. 2025; 27(2).

PMID: 39836612 PMC: 11795656. DOI: 10.1093/europace/euaf010.


First-in-human trial of atrial fibrillation ablation using real-time tissue optical assessment to predict pulsed field lesion durability.

Martins R, Papiashvili G, Sabirov A, Sabirov S, Herranz D, Bailleul C Europace. 2025; 27(2).

PMID: 39824175 PMC: 11832195. DOI: 10.1093/europace/euaf009.


References
1.
Chen J, Arentz T, Cochet H, Muller-Edenborn B, Kim S, Moreno-Weidmann Z . Extent and spatial distribution of left atrial arrhythmogenic sites, late gadolinium enhancement at magnetic resonance imaging, and low-voltage areas in patients with persistent atrial fibrillation: comparison of imaging vs. electrical parameters of.... Europace. 2019; 21(10):1484-1493. DOI: 10.1093/europace/euz159. View

2.
Kistler P, Chieng D, Sugumar H, Ling L, Segan L, Azzopardi S . Effect of Catheter Ablation Using Pulmonary Vein Isolation With vs Without Posterior Left Atrial Wall Isolation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The CAPLA Randomized Clinical Trial. JAMA. 2023; 329(2):127-135. PMC: 9856612. DOI: 10.1001/jama.2022.23722. View

3.
Creta A, Kanthasamy V, Schilling R, Rosengarten J, Khan F, Honarbakhsh S . First experience of POLARx™ versus Arctic Front Advance™: An early technology comparison. J Cardiovasc Electrophysiol. 2021; 32(4):925-930. DOI: 10.1111/jce.14951. View

4.
Sawhney V, Schilling R, Providencia R, Cadd M, Perera D, Chatha S . Cryoablation for persistent and longstanding persistent atrial fibrillation: results from a multicentre European registry. Europace. 2019; 22(3):375-381. DOI: 10.1093/europace/euz313. View

5.
Kautzner J, Albenque J, Natale A, Maddox W, Cuoco F, Neuzil P . A Novel Temperature-Controlled Radiofrequency Catheter Ablation System Used to Treat Patients With Paroxysmal Atrial Fibrillation. JACC Clin Electrophysiol. 2021; 7(3):352-363. DOI: 10.1016/j.jacep.2020.11.009. View